Use the interactive map below to see if there is a site near you. To identify the site nearest you, simply enter your zip code in the search field below. If you are interested in learning more, you can contact the site directly or submit your information here.
The following are some frequently asked questions (FAQ'S) about INHALE-1.
The study is being done to find out if inhaled insulin plus basal insulin injections work as effectively and safely as taking all insulin by injections in children and teenagers with diabetes. Inhaled insulin was FDA-approved for use in adults in 2014.
You can evaluate your child/teenager’s eligibility by entering his/her information into the pre-qualification form. You can also review the eligibility criteria listed on ClinTrials.gov (https://www.clinicaltrials.gov/study/NCT04974528?term=inhale-1&rank=1).
The research may help people with diabetes in the future. Your child/teenager may need fewer injections for their diabetes management. A CGM will be provided to participants for use in the study at no cost.
The most common and expected side effects and discomforts reported for inhaled insulin are low blood sugar, cough, and sore throat.
Your child/teenager is eligible for the study once he/she has been off an insulin pump for at least 2 weeks. Please talk to a health care provider before stopping your child's insulin pump.
There are currently over 35 active sites across the US! You can find a list of sites on this webpage in the Study Locations section or on ClinTrials.gov (https://www.clinicaltrials.gov/study/NCT04974528?term=inhale-1&rank=1). Additionally, you can enter information into the pre-qualification form and you will be paired with a nearby site. If a nearby site is not immediately available, enter your information anyway and you will be contacted once a nearby site becomes available.
You can review more details on the study by going to ClinTrials.gov (https://www.clinicaltrials.gov/study/NCT04974528?term=inhale-1&rank=1).
"Children Are Not Little Adults: The Importance of Pediatric Research” - JDRF and MannKind Corporation discuss the importance of pediatric type 1 diabetes (T1D) research from both the patient and clinician perspective.